A Belatacept Compassionate Use Study for Patients With a Kidney Transplant

NO_LONGER_AVAILABLE

Conditions studied: Renal Transplantation

In brief

To make belatacept available for recipients of a renal allograft who are currently intolerant to or have contraindications to CNIs and/or m-TOR inhibitors and are either: * unable to construct an adequate immunosuppression regimen due to nonrenal toxicity / contraindication (and withdrawing the causative agent would lead to renal graft loss) OR * at imminent risk of losing the allograft kidney due to nephrotoxicity and have no other options for renal replacement therapy

Key facts

Study ID
NCT00719225
Run by
Bristol-Myers Squibb
Last updated by the study team
2021-11-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.